The consequences
of hyperkalaemia

Hyperkalaemia is unpredictable, may often reoccur, and the consequences may be life-threatening.1,2

This website provides healthcare professionals (HCPs) with information on the impact of hyperkalaemia in these high-risk patients, including the effect on RAASi (renin-angiotensin-aldosterone system inhibitors) dosing and clinical outcomes

This site is for non-US, non-UK healthcare professionals only.

References:

  1. Thomsen RW et al. Nephrol Dial Transplant. 2017: 1–10. [Epub ahead of print]
  2. UK Renal Association Clinical Practice Guidelines. 2014. Treatment of Acute Hyperkalaemia in Adults.
Green Kidney icon

Chronic
kidney disease

Hyperkalaemia can be a recurrent problem in patients with CKD, which is associated with an increased risk of hospitalisation*1 and mortality.**2  

*Compared to matched cohorts without hyperkalaemia.

**Compared to a normokalaemia range K+≥3.5-5 mEq/L.

References:

  1. Thomsen RW et al. Nephrol Dial Transplant. 2017: 1–10.
  2. Qin L, et al. ERA-EDTA, Madrid, 2017. Poster presentation MO067.
Orange Heart icon

Heart failure

Hyperkalaemia is common in patients with heart failure, which can prevent patients achieving guideline recommended RAASi.1-3 

*RAASi, renin-angiotensin-aldosterone system inhibitors

References:

  1. Nilsson E, et al. ERA-EDTA, Madrid, 2017. Poster presentation SP313.
  2. Epstein M et al. Am J Manag Care 2015; 21: S212-S220.
  3. Maggioni AP et al. Eur J Heart Fail. 2013; 15: 1173-84.
Co-morbid conditions

Co-morbid
conditions

Some co-morbid conditions increase  a patient’s risk of developing  hyperkalaemia, which is associated  with poor clinical outcomes.1,2 

  1. Thomsen RW et al. Nephrol Dial Transplant. 2017: 1–10. [Epub ahead of print]
  2. Qin L, et al. ERA-EDTA, Madrid, 2017. Poster presentation MO067.
Blue Pill icon

RAASi therapy

Hyperkalaemia and subsequent  suboptimal RAASi treatment is associated with increased morbidity and mortality. *1

*Compared to optimal RAASi treatment

RAASi, renin-angiotensin-aldosterone system inhibitors

References:

  1. Epstein M et al. Am J Manag Care 2015; 21: S212-S220.

There is a need for
additional treatment
options for the management
of hyperkalaemia.1

Click the links below to discover the impact of
hyperkalaemia on patients with different conditions.

CKD PATIENTS
HF PATIENTS
CO-MORBIDITIES

  1. National Kidney Foundation. 2014. Clinical update on hyperkalaemia.